Lucid Diagnostics (LUCD) said Friday it closed its public offering of about 14.4 million common shares, including roughly 1.9 million shares issued pursuant to the exercise of the underwriters' overallotment option, at $1.20 per share.
The net proceeds of about $16.1 million will be used for working capital and general corporate purposes, according to the company, which is a unit of PAVmed (PAVM).
Price: 1.23, Change: -0.02, Percent Change: -2.00